Social Media Ideas for Biib

BioXcel files for Chapter 11, will sell assets to Teva

Biogen upgraded at JPMorgan with $300 PT on 2027 pipeline catalysts, shares rise

Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)

BioXcel

BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...

BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

<![CDATA[FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B]]>

GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication f...

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication...

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

<![CDATA[Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

<![CDATA[FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy ]...

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

IGIB: A 5.9% Yield, Tight Spreads And A Rate-Driven Slump

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow

<![CDATA[Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic]]>

IBEX Limited 2026 Q4 - Results - Earnings Call Presentation

Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could c...

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease...

Syngene Expands Integrated Drug Development and Manufacturing Services with BMS

The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center, Synge...

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

BridgeBio

BridgeBio Anonymous (not verified) Tue, 10/13/2026 - 07:11 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...